drugset / Trial / NCT03832361
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Timeline
- Start
- 2020-07-15
- Primary completion
- 2026-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 6 mg/kg | Intravenous |